Shots:
- The P-IIb POC Study 201 involves assessing lecanemab in patients with early AD
- Results: @18mos, prespecified analysis showed a consistent reduction of clinical decline across several clinical and biomarker EPs at highest doses and reduction in brain Aβ & clinical decline. The results are published in a peer-reviewed journal
- In March, the companies have completed the enrolment in P-III OLE, Clarity AD trial that evaluate the safety & efficacy of lecanemab vs PBO in 1,795 symptomatic patients with early AD, following the outcome of P-IIb study. Additionally, the P-III AHEAD 3-45 study is currently evaluating lecanemab in individuals with preclinical AD
Click here to read full press release/ article | Ref: PRNewswire | Image: Wikipedia
The post Biogen and Eisai Report Results of Lecanemab (BAN2401) in P-IIb Study 201 for Patients with Early Alzheimer Disease first appeared on PharmaShots.
